GW Pharmaceuticals PLC- (NASDAQ:GWPH) rose 5.5% during trading on Tuesday . The stock traded as high as $111.82 and last traded at $111.16, with a volume of 430,258 shares traded. The stock had previously closed at $105.41.

GWPH has been the topic of several research analyst reports. Piper Jaffray Cos. restated an “overweight” rating and set a $147.00 target price on shares of GW Pharmaceuticals PLC- in a research report on Saturday, August 13th. Vetr upgraded shares of GW Pharmaceuticals PLC- from a “buy” rating to a “strong-buy” rating and set a $91.16 target price on the stock in a research report on Wednesday, August 17th. Zacks Investment Research lowered shares of GW Pharmaceuticals PLC- from a “buy” rating to a “hold” rating in a research report on Friday, July 29th. Bank of America Corp. restated a “buy” rating and set a $153.00 target price on shares of GW Pharmaceuticals PLC- in a research report on Monday, July 18th. Finally, Leerink Swann restated a “buy” rating and set a $130.00 target price on shares of GW Pharmaceuticals PLC- in a research report on Tuesday, June 21st. One research analyst has rated the stock with a sell rating, two have issued a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. GW Pharmaceuticals PLC- has an average rating of “Buy” and a consensus price target of $126.01.

The stock’s market capitalization is $2.40 billion. The firm’s 50-day moving average is $90.62 and its 200 day moving average is $84.50.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/gw-pharmaceuticals-plc-gwph-stock-price-up-5-5.html

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last issued its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.21) by $1.15. The company earned $3.10 million during the quarter, compared to analyst estimates of $3.63 million. During the same period in the prior year, the business earned ($0.09) earnings per share. GW Pharmaceuticals PLC-‘s quarterly revenue was down 73.3% on a year-over-year basis. On average, analysts expect that GW Pharmaceuticals PLC- will post ($3.12) earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. IFP Advisors Inc boosted its position in shares of GW Pharmaceuticals PLC- by 5.7% in the second quarter. IFP Advisors Inc now owns 1,859 shares of the biopharmaceutical company’s stock valued at $170,000 after buying an additional 100 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of GW Pharmaceuticals PLC- by 2.4% in the first quarter. Geode Capital Management LLC now owns 6,072 shares of the biopharmaceutical company’s stock valued at $438,000 after buying an additional 141 shares in the last quarter. ProShare Advisors LLC boosted its position in shares of GW Pharmaceuticals PLC- by 1.6% in the second quarter. ProShare Advisors LLC now owns 11,496 shares of the biopharmaceutical company’s stock valued at $1,053,000 after buying an additional 176 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. boosted its position in shares of GW Pharmaceuticals PLC- by 12.3% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,960 shares of the biopharmaceutical company’s stock valued at $141,000 after buying an additional 214 shares in the last quarter. Finally, Commonwealth Equity Services Inc boosted its position in shares of GW Pharmaceuticals PLC- by 3.3% in the second quarter. Commonwealth Equity Services Inc now owns 8,103 shares of the biopharmaceutical company’s stock valued at $742,000 after buying an additional 262 shares in the last quarter.

About GW Pharmaceuticals PLC-

GW Pharmaceuticals plc is involved in the development of cannabinoid prescription medicines using botanical extracts derived from the Cannabis Sativa plant. The Company develops a portfolio of cannabinoid medicines, including Epidiolex, which is an oral medicine for the treatment of refractory childhood epilepsies.

5 Day Chart for NASDAQ:GWPH

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.